FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2161984323> ?p ?o ?g. }

• W2161984323 endingPage "4364" @default.
• W2161984323 startingPage "4357" @default.
• W2161984323 abstract "Purpose To determine the maximum-tolerated dose (MTD) and efficacy of pralatrexate in patients with lymphoma. Patients and Methods Pralatrexate, initially given at a dose of 135 mg/m 2 on an every-other-week basis, was associated with stomatitis. A redesigned, weekly phase I/II study established an MTD of 30 mg/m 2 weekly for six weeks every 7 weeks. Patients were required to have relapsed/refractory disease, an absolute neutrophil greater than 1,000/μL, and a platelet count greater than 50,000/μL for the first dose of any cycle. Results The every-other-week, phase II experience was associated with an increased risk of stomatitis and hematologic toxicity. On a weekly schedule, the MTD was 30 mg/m 2 weekly for 6 weeks every 7 weeks. This schedule modification resulted in a 50% reduction in the major hematologic toxicities and abrogation of the grades 3 to 4 stomatitis. Stomatitis was associated with elevated homocysteine and methylmalonic acid, which were reduced by folate and vitamin B12 supplementation. Of 48 assessable patients, the overall response rate was 31% (26% by intention to treat), including 17% who experienced complete remission (CR). When analyzed by lineage, the overall response rates were 10% and 54% in patients with B- and T-cell lymphomas, respectively. All eight patients who experienced CR had T-cell lymphoma, and four of the six patients with a partial remission were positron emission tomography negative. The duration of responses ranged from 3 to 26 months. Conclusion Pralatrexate has significant single-agent activity in patients with relapsed/refractory T-cell lymphoma." @default.
• W2161984323 created "2016-06-24" @default.
• W2161984323 creator A5001102192 @default.
• W2161984323 creator A5002126535 @default.
• W2161984323 creator A5004887408 @default.
• W2161984323 creator A5005126836 @default.
• W2161984323 creator A5012023084 @default.
• W2161984323 creator A5012521956 @default.
• W2161984323 creator A5012810450 @default.
• W2161984323 creator A5019593638 @default.
• W2161984323 creator A5026935093 @default.
• W2161984323 creator A5031311239 @default.
• W2161984323 creator A5041344703 @default.
• W2161984323 creator A5053648375 @default.
• W2161984323 creator A5061964017 @default.
• W2161984323 creator A5063481171 @default.
• W2161984323 creator A5065503391 @default.
• W2161984323 creator A5069406522 @default.
• W2161984323 creator A5082894654 @default.
• W2161984323 date "2009-09-10" @default.
• W2161984323 modified "2023-09-26" @default.
• W2161984323 title "Phase II-I-II Study of Two Different Doses and Schedules of Pralatrexate, a High-Affinity Substrate for the Reduced Folate Carrier, in Patients With Relapsed or Refractory Lymphoma Reveals Marked Activity in T-Cell Malignancies" @default.
• W2161984323 cites W1912693401 @default.
• W2161984323 cites W1965062797 @default.
• W2161984323 cites W1973678951 @default.
• W2161984323 cites W1985025279 @default.
• W2161984323 cites W1990318898 @default.
• W2161984323 cites W1990493121 @default.
• W2161984323 cites W2054268096 @default.
• W2161984323 cites W2108798437 @default.
• W2161984323 cites W2149195756 @default.
• W2161984323 cites W2597344454 @default.
• W2161984323 cites W60865865 @default.
• W2161984323 doi "https://doi.org/10.1200/jco.2008.20.8470" @default.
• W2161984323 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/3651599" @default.
• W2161984323 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/19652067" @default.
• W2161984323 hasPublicationYear "2009" @default.
• W2161984323 type Work @default.
• W2161984323 sameAs 2161984323 @default.
• W2161984323 citedByCount "164" @default.
• W2161984323 countsByYear W21619843232012 @default.
• W2161984323 countsByYear W21619843232013 @default.
• W2161984323 countsByYear W21619843232014 @default.
• W2161984323 countsByYear W21619843232015 @default.
• W2161984323 countsByYear W21619843232016 @default.
• W2161984323 countsByYear W21619843232017 @default.
• W2161984323 countsByYear W21619843232018 @default.
• W2161984323 countsByYear W21619843232019 @default.
• W2161984323 countsByYear W21619843232020 @default.
• W2161984323 countsByYear W21619843232021 @default.
• W2161984323 countsByYear W21619843232022 @default.
• W2161984323 countsByYear W21619843232023 @default.
• W2161984323 crossrefType "journal-article" @default.
• W2161984323 hasAuthorship W2161984323A5001102192 @default.
• W2161984323 hasAuthorship W2161984323A5002126535 @default.
• W2161984323 hasAuthorship W2161984323A5004887408 @default.
• W2161984323 hasAuthorship W2161984323A5005126836 @default.
• W2161984323 hasAuthorship W2161984323A5012023084 @default.
• W2161984323 hasAuthorship W2161984323A5012521956 @default.
• W2161984323 hasAuthorship W2161984323A5012810450 @default.
• W2161984323 hasAuthorship W2161984323A5019593638 @default.
• W2161984323 hasAuthorship W2161984323A5026935093 @default.
• W2161984323 hasAuthorship W2161984323A5031311239 @default.
• W2161984323 hasAuthorship W2161984323A5041344703 @default.
• W2161984323 hasAuthorship W2161984323A5053648375 @default.
• W2161984323 hasAuthorship W2161984323A5061964017 @default.
• W2161984323 hasAuthorship W2161984323A5063481171 @default.
• W2161984323 hasAuthorship W2161984323A5065503391 @default.
• W2161984323 hasAuthorship W2161984323A5069406522 @default.
• W2161984323 hasAuthorship W2161984323A5082894654 @default.
• W2161984323 hasBestOaLocation W21619843232 @default.
• W2161984323 hasConcept C121332964 @default.
• W2161984323 hasConcept C126322002 @default.
• W2161984323 hasConcept C141071460 @default.
• W2161984323 hasConcept C142424586 @default.
• W2161984323 hasConcept C2777063308 @default.
• W2161984323 hasConcept C2778496288 @default.
• W2161984323 hasConcept C2779051857 @default.
• W2161984323 hasConcept C2779338263 @default.
• W2161984323 hasConcept C29730261 @default.
• W2161984323 hasConcept C31760486 @default.
• W2161984323 hasConcept C71924100 @default.
• W2161984323 hasConcept C87355193 @default.
• W2161984323 hasConcept C90924648 @default.
• W2161984323 hasConceptScore W2161984323C121332964 @default.
• W2161984323 hasConceptScore W2161984323C126322002 @default.
• W2161984323 hasConceptScore W2161984323C141071460 @default.
• W2161984323 hasConceptScore W2161984323C142424586 @default.
• W2161984323 hasConceptScore W2161984323C2777063308 @default.
• W2161984323 hasConceptScore W2161984323C2778496288 @default.
• W2161984323 hasConceptScore W2161984323C2779051857 @default.
• W2161984323 hasConceptScore W2161984323C2779338263 @default.
• W2161984323 hasConceptScore W2161984323C29730261 @default.
• W2161984323 hasConceptScore W2161984323C31760486 @default.
• W2161984323 hasConceptScore W2161984323C71924100 @default.
• W2161984323 hasConceptScore W2161984323C87355193 @default.
• W2161984323 hasConceptScore W2161984323C90924648 @default.
• W2161984323 hasIssue "26" @default.

• next